 Fluorodeoxyglucose F18
"Fluorodeoxyglucose F18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
| Descriptor ID |
D019788
|
| MeSH Number(s) |
D09.254.229.500
|
| Concept/Terms |
Fluorodeoxyglucose F18- Fluorodeoxyglucose F18
- F18, Fluorodeoxyglucose
- 18F-FDG
- Fluorodeoxyglucose F 18
- F 18, Fluorodeoxyglucose
- Fludeoxyglucose F 18
- F 18, Fludeoxyglucose
- Fluorine-18-fluorodeoxyglucose
- Fluorine 18 fluorodeoxyglucose
- 18F Fluorodeoxyglucose
- Fluorodeoxyglucose, 18F
- 18FDG
|
Below are MeSH descriptors whose meaning is more general than "Fluorodeoxyglucose F18".
Below are MeSH descriptors whose meaning is more specific than "Fluorodeoxyglucose F18".
This graph shows the total number of publications written about "Fluorodeoxyglucose F18" by people in this website by year, and whether "Fluorodeoxyglucose F18" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 0 | 2 | 2 | | 1991 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 2002 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 2 | 1 | 3 | | 2007 | 4 | 2 | 6 | | 2009 | 1 | 2 | 3 | | 2010 | 5 | 2 | 7 | | 2011 | 2 | 2 | 4 | | 2012 | 4 | 3 | 7 | | 2013 | 3 | 3 | 6 | | 2014 | 3 | 2 | 5 | | 2015 | 2 | 2 | 4 | | 2016 | 1 | 4 | 5 | | 2017 | 3 | 6 | 9 | | 2018 | 0 | 4 | 4 | | 2019 | 0 | 1 | 1 | | 2020 | 2 | 2 | 4 | | 2021 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluorodeoxyglucose F18" by people in Profiles.
-
Josephs KA, Duffy JR, Clark HM, Utianski RL, Strand EA, Machulda MM, Botha H, Martin PR, Pham NTT, Stierwalt J, Ali F, Buciuc M, Baker M, Fernandez De Castro CH, Spychalla AJ, Schwarz CG, Reid RI, Senjem ML, Jack CR, Lowe VJ, Bigio EH, Reichard RR, Polley EJ, Ertekin-Taner N, Rademakers R, DeTure MA, Ross OA, Dickson DW, Whitwell JL. A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nat Commun. 2021 06 08; 12(1):3452.
-
Zhang HJ, Mitchell S, Fang YH, Tsai HM, Piao L, Ousta A, Leoni L, Chen CT, Sharp WW. Assessment of Brain Glucose Metabolism Following Cardiac Arrest by [18F]FDG Positron Emission Tomography. Neurocrit Care. 2021 02; 34(1):64-72.
-
Kebed KY, Carter SV, Flatley E, Ward RP, Moss JD, Appelbaum DE, Singh A, Lang RM, Tung R, Patel AR. Prevalence of newly diagnosed sarcoidosis in patients with ventricular arrhythmias: a cardiac magnetic resonance and 18F-FDG cardiac PET study. Int J Cardiovasc Imaging. 2021 Apr; 37(4):1361-1369.
-
Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020 06 18; 135(25):2224-2234.
-
Platek A, Mix M, Chowdhry V, Farrugia M, Lacombe MA, Bogart JA, Degraaf L, Iovoli A, Arshad H, Wooten K, Gupta V, Hicks WL, Platek ME, Hahn SS, Singh AK. Evaluation of radiation treatment volumes for unknown primaries of the head and neck in the era of FDG PET. PLoS One. 2020; 15(4):e0231042.
-
Akiyama S, Traboulsi C, Rai V, Rubin DT. Re: 18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. Eur J Nucl Med Mol Imaging. 2020 09; 47(10):2247.
-
Kernstine KH, Faubert B, Do QN, Rogers TJ, Hensley CT, Cai L, Torrealba J, Oliver D, Wachsmann JW, Lenkinski RE, Malloy CR, Deberardinis RJ. Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer? Ann Thorac Surg. 2020 04; 109(4):1019-1025.
-
Goyal A, Dey AK, Chaturvedi A, Elnabawi YA, Aberra TM, Chung JH, Belur AD, Groenendyk JW, Lerman JB, Rivers JP, Rodante JA, Harrington CL, Varghese NJ, Sanda GE, Baumer Y, Sorokin AV, Teague HL, Genovese LD, Natarajan B, Joshi AA, Playford MP, Bluemke DA, Chen MY, Alavi A, Pitman RK, Powell-Wiley TM, Tawakol A, Gelfand JM, Mehta NN. Chronic Stress-Related Neural Activity Associates With Subclinical Cardiovascular Disease in Psoriasis: A Prospective Cohort Study. JACC Cardiovasc Imaging. 2020 02; 13(2 Pt 1):465-477.
-
Finkle JH, Penney BC, Pu Y. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2018 09; 123:136-141.
-
Pu Y, Zhang JX, Liu H, Appelbaum D, Meng J, Penney BC. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2079-2092.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|